{
    "clinical_study": {
        "@rank": "114371", 
        "arm_group": [
            {
                "arm_group_label": "Dorsal zona incerta", 
                "arm_group_type": "Experimental", 
                "description": "Up to 3 mA, 60 us, 130 Hz deep brain stimulation"
            }, 
            {
                "arm_group_label": "Caudal zona incerta", 
                "arm_group_type": "Experimental", 
                "description": "Up to 3 mA, 60 us, 130 Hz deep brain stimulation"
            }, 
            {
                "arm_group_label": "Empirical deep brain stimulation", 
                "arm_group_type": "Experimental", 
                "description": "Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome."
            }
        ], 
        "brief_summary": {
            "textblock": "The posterior subthalamic area holds promise as a target region for deep brain stimulation\n      in tremor and Parkinson's disease. Using the magnetic resonance-directed implantable guide\n      tube surgical technique, subregions of the posterior subthalamic area can be individually\n      targetted on a single electrode lead trajectory. The hypothesis is that the caudal zona\n      incerta may provide improved control of movement disorder symptoms than the more commonly\n      stimulated dorsal zona incerta."
        }, 
        "brief_title": "Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Parkinson's Disease", 
            "Tremor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Tremor"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomisation between two treatment locations each programmed up to 3 milliamps in amplitude\n      for 3 months: (1) caudal zona incerta and (2) dorsal zona incerta. This 6-month-long\n      randomised phase is followed by 6 months of unblinded individualised empirically optimised\n      settings programmed by a neurologist. Each of the three treatment periods ends with a full\n      clinical, functional and quality of life assessment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medication-refractory tremor and/or Parkinson's disease as defined by UK Brain Bank\n             criteria with either inadequate control of motor fluctuations or dyskinesia despite\n             optimised medical therapy\n\n        Exclusion Criteria:\n\n          -  Significant cognitive, psychiatric and medical co-morbidities\n\n          -  Dementia with mini mental state examination score of less than 25/30\n\n          -  Limited life expectancy due to a co-morbid condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945567", 
            "org_study_id": "2012-039"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dorsal zona incerta", 
                    "Caudal zona incerta"
                ], 
                "intervention_name": "Up to 3 mA, 60 us, 130 Hz deep brain stimulation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Empirical deep brain stimulation", 
                "intervention_name": "Empirical unblinded deep brain stimulation programming", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson's disease", 
            "Essential tremor", 
            "Tremor", 
            "Deep brain stimulation", 
            "Posterior subthalamic area", 
            "Zona incerta"
        ], 
        "lastchanged_date": "September 17, 2013", 
        "link": [
            {
                "description": "Surgical NeuroDiscovery Group", 
                "url": "http://www.neurofinity.org"
            }, 
            {
                "description": "Neurosurgical Service of Western Australia, Sir Charles Gairdner Hospital", 
                "url": "http://www.scgh.health.wa.gov.au/OurServices/Neurosurgery/index.html"
            }, 
            {
                "description": "School of Surgery, University of Western Australia", 
                "url": "http://www.surgery.uwa.edu.au/"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Perth", 
                    "country": "Australia", 
                    "state": "Western Australia", 
                    "zip": "6009"
                }, 
                "name": "Sir Charles Gairdner Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor", 
        "overall_contact": {
            "email": "Christopher.Lind@health.wa.gov.au", 
            "last_name": "Christopher Lind, MBChB, FRACS", 
            "phone": "+61 8 9346 2865"
        }, 
        "overall_contact_backup": {
            "email": "Megan.Thorburn@health.wa.gov.au", 
            "last_name": "Megan Thorburn, RN"
        }, 
        "overall_official": {
            "affiliation": "The University of Western Australia", 
            "last_name": "Christopher Lind, MBChB, FRACS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "At end of first randomised crossover trial period", 
                "measure": "Change from baseline United Parkinsons Disease Rating Scale Part III at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover trial period", 
                "measure": "Change from baseline United Parkinsons Disease Rating Scale Part III at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of non-randomised empirical deep brain stimulator programming period", 
                "measure": "Change from baseline United Parkinsons Disease Rating Scale Part III at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover trial period for tremor patients", 
                "measure": "Change from baseline Fahn Tolosa Marin tremor scale at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover trial period for tremor patients", 
                "measure": "Change from baseline Fahn Tolosa Marin tremor scale at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period for tremor patients", 
                "measure": "Change from baseline Fahn Tolosa Marin tremor scale at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945567"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Western Australia", 
            "investigator_full_name": "Professor Christopher Lind", 
            "investigator_title": "Professor, School of Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "For Parkinson's disease", 
                "measure": "Change from baseline ON-OFF diary at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "For Parkinson's disease", 
                "measure": "Change from baseline ON-OFF diary at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "For Parkinson's disease", 
                "measure": "Change from baseline ON-OFF diary at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Any adverse medical event from date of randomization until the date of first documented adverse event or date of death from any cause, whichever came first, assessed up to 12 months", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period", 
                "measure": "Change from baseline Short form 36 at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period", 
                "measure": "Change from baseline Short form 36 at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period", 
                "measure": "Change from baseline Short form 36 at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline Parkinsons Disease Quality of Life 39 at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline Parkinsons Disease Quality of Life 39 at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period for Parkinsons disease", 
                "measure": "Change from baseline Parkinsons Disease Quality of Life 39 at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline L-dopa equivalent dose at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline L-dopa equivalent dose at 6 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period for Parkinsons disease", 
                "measure": "Change from baseline L-dopa equivalent dose at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period", 
                "measure": "Change from baseline neuropsychological battery at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period", 
                "measure": "Change from baseline neuropsychological battery at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period", 
                "measure": "Change from baseline neuropsychological battery at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period", 
                "measure": "Change from baseline verbal fluency at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period", 
                "measure": "Change from baseline verbal fluency at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period", 
                "measure": "Change from baseline verbal fluency at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period", 
                "measure": "Change from baseline Mini-International Neuropsychiatric Interview Plus at 3 months", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period", 
                "measure": "Change from baseline Mini-International Neuropsychiatric Interview Plus at 6 months", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period", 
                "measure": "Change from baseline Mini-International Neuropsychiatric Interview Plus at 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period for Parkinsons disease", 
                "measure": "Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "At end of first randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline Abnormal Involuntary Movement Scale at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "At end of second randomised crossover period for Parkinsons disease", 
                "measure": "Change from baseline Abnormal Involuntary Movement Scale at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At end of empirical deep brain stimulator programming period for Parkinsons disease", 
                "measure": "Change from baseline Abnormal Involuntary Movement Scale at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "The University of Western Australia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Western Australia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}